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Since 2013, the 13-valent pneumococcal conjugate 
vaccine (PCV  13) has been recommended in chil-
dren and adolescents aged 6–17  years, regardless of 
whether they are healthy (Rubin et al., 2014) or suf-
fer from immunocompromising conditions such as 
IBD (CDC, 2013). At the time of this study very little 
research has been conducted to determine the serologi-
cal status of older children and adolescentswith respect 
to the 13 PCV serotypes. Only two studies have been 
conducted to date: one in healthy young Americans 
(Frenck Jr. et al., 2014) and one in children and adoles-
cents with perinatally acquired HIV infection in Africa 
(Bamford et al., 2014). Differences in preimmunization 
pneumococcal vaccine-specific serological status were 
observed between these studies. This could be explained 
by worldwide differences in pneumococcal serotype 
distribution modifying the natural response and by the 
impaired serological response of HIV-infected children. 
A recently published study assessed the prevaccination 
serological status of older Polish infants and toddlers 
who were naïve to pneumococcal vaccination (Wysocki 
et al., 2015). The aim of this report was to assess the 
pneumococcal serological status of older Polish chil-
dren and adolescents with IBD prior to the administra-
tion of one dose of PCV 13. 
This report was part of an open, prospective study 
that was conducted between April 2013 and March 
2014 across six hospitals in Poland (cities of Warsaw, 
Poznan, Wroclaw, Katowice, Gdansk and Cracow) 
to compare the immunogenicity and safety of using 
PCV 13 in subjects with IBD versus healthy controls 
(grant of the Polish Ministry of Science and Higher 
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A b s t r a c t
The aim of this study was to evaluate the serotype-specific pneumococcal status of children and adolescents with inflammatory bowel 
disease (IBD) who were naïve to pneumococcal vaccination before administering the 13-valent pneumococcal conjugate vaccine (PCV 13). 
This was an open, prospective study on children and adolescents aged 5–18 years who had IBD and were naïve to pneumococcal vac-
cination. A single dose of PCV 13 was administered to each patient. The geometric mean concentrations (GMCs) were measured for all 
13 serotypes. A total of 122 subjects completed the study. Prevaccination GMCs ranged from 0.55 µg/ml (serotype 4) to 4.26 µg/ml (sero-
type 19A). Prior to the administration of PCV 13, high GMCs were detected in older children and adolescents who had IBD and were 
naïve to pneumococcal vaccination.
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Education no. N404 077140 0771/B/P01/2011/40). Our 
part of the study focused on subjects between 5 and 
18 years of age who had been diagnosed with IBD based 
on clinical signs and symptoms in addition to endo-
scopic, histologic and radiologic results, according to 
the Porto criteria (Levine et al., 2014). Additionally, the 
subjects had not been previously vaccinated with any 
of pneumococcal vaccines and had no history of IPD. 
IBD patients were included from any stage of the dis-
ease and treatment process. All participants received 
one dose of 0.5 ml 13-valent PCV (Diphtheria CRM197 
Protein) from Wyeth Pharmaceuticals, Inc. Blood sam-
ples were collected immediately prior to vaccination. 
Sera were stored at –20°C to –70°C until analysis was 
performed. Each serum sample was tested for sero-
type-specific anti-pneumococcal polysaccharide IgG 
antibodies to the 13 polysaccharides of PCV13 (1, 3, 
4, 5, 6A, 6B, 7F, 9 V, 14, 18C, 19A, 19F and 23F) using 
a  standardized enzyme linked immunoassay accord-
ing to an adapted WHO protocol (WHO, 2005). To 
enhance the specificity of the serotype-specific anti-
bodies, the assay included the preabsorption of test 
sera from the pneumococcal C polysaccharide and the 
pneumococcal polysaccharide from the non-vaccine 
22F serotype (Wernette et al., 2003; Concepcion et al., 
2001). All parents and children ≥ 16 years old provided 
written informed consent. Geometric mean concentra-
tions (GMCs) of prevaccination antibody levels were 
used as the measure of central tendency. Confidence 
intervals at 1 – α = 0.05 were computed (CI 95%). This 
study was approved on Jan 26th 2010 by the Clinical 
Research Ethics Committee of the Medical University 
of Warsaw, Poland. This study was supported by grant 
no. N404 077140 0771/B/P01/2011/40 from the Polish 
Ministry of Science and Higher Education. The project 
was approved Febr. 4th, 2010.
This study included 122 older children and adoles-
cents who had IBD (mean age 15.08 years, 60% boys). 
The prevaccination GMCs are presented in Table I.
In this report, we found high prevaccination GMCs 
for all 13 serotypes (range from 0.55 µg/ml for serotype 
4 to 4.26 for serotype 19A). This is in accordance with 
previous studies conducted on healthy older children 
(Frenck Jr et al., 2014; Wysocki et al., 2015) and ado-
lescents (Frenck Jr et al., 2014). These findings support 
the suggestion of natural exposure to vaccine serotypes. 
Notably, we observed high GMCs for both the most 
common (1, 14 and 19F) and the most fatal (3, 4, 19F, 
14 and 19A) serotypes in Polish 5- to 25-year-old sub-
jects with IPD (Skoczyńska et al., 2015). For children 
with chronic, potentially immunosuppressing condi-
tions such as IBD, protection against a significant pro-
portion of the serotypes that can cause IPD is extremely 
important. However, mass vaccination against pneumo-
coccal disease has not yet been introduced in Poland. 
We hope that the relatively high prevaccination GMCs 
that were observed will also offer protection against 
non-IPD; however, the concentration that would be 
required to confer protection against pneumococcal 
non-bacteremic pneumonia and pneumococcal otitis 
media remains unknown.
Our report has several advantages. Our work is 
only the second study to assess the use of PCV13 in 
older children and adolescents who are naïve to pneu-
mococcal vaccines. Our study also provides data on 
the serological status of patients who were suffering 
from a chronic disease prior to the administration of 
PCV13 and adds evidence to the hypothesis that natu-
ral exposure to pneumococcal vaccine serotypes occurs 
in Poland: a country with very low PCV coverage and 
a lack of herd immunity. PCVs are still not part of the 
national vaccine program, and patients who elect to 
have vaccines are not reimbursed; thus, they are only 
available to a very small proportion of Polish children. 
Although our study group was small, it was still large 
enough to perform statistical analysis. A shortcoming 
of the present study is the lack of a functional response 
measurement for the serotypes.
High prevaccination pneumococcal GMCs of all 
PCV  13 serotypes were found in children and ado-
lescents with IBD, suggesting that they previously 
acquired natural protection against IPD but not neces-
sarily against non-IPD.
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